Summary:
The A4 study (also known as the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study) is a landmark clinical trial to prevent the memory loss associated with Alzheimer's disease. The A4 study is for individuals ages 65 to 85 who may be at risk for AD-related memory loss but who have no outward signs of the disease.
The A4 study is investigating a new treatment that may reduce the impact of a protein known as "amyloid" or "beta amyloid" which forms plaques in the brain. Scientists believe that the accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.
Qualified Participants Must:
• Be between 65 and 85 years of age
•
Have normal thinking and memory abilities
•
Have a study partner who has at least weekly contact with you and can answer questions once a year
•
If positive on the amyloid PET scan, willing to have intravenous infusions of the investigational treatment or placebo (monthly infusions)
Qualified Participants May Receive:
Complete memory work up including:
Memory and thinking tests
ECGs
PET scan
MRI scan
Blood and Urine Tests
$50 stipend per visit for both subject and study partner